Literature DB >> 19001032

Heart failure after acute myocardial infarction: a lost battle in the war on heart failure?

Pardeep S Jhund, John J V McMurray.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 19001032     DOI： 10.1161/CIRCULATIONAHA.108.813493

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  42 in total

1.  Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study.

Authors:  Yariv Gerber; Susan A Weston; Cecilia Berardi; Sheila M McNallan; Ruoxiang Jiang; Margaret M Redfield; Véronique L Roger
Journal:  Am J Epidemiol       Date:  2013-08-29       Impact factor: 4.897

Review 2.  Exosome and its roles in cardiovascular diseases.

Authors:  Wang Zhao; Xi-Long Zheng; Shui-Ping Zhao
Journal:  Heart Fail Rev       Date:  2015-05       Impact factor: 4.214

3.  Exogenous IL-19 attenuates acute ischaemic injury and improves survival in male mice with myocardial infarction.

Authors:  Weishuai An; Yongsheng Yu; Yuefan Zhang; Zhigang Zhang; Yunhua Yu; Xianxian Zhao
Journal:  Br J Pharmacol       Date:  2019-01-08       Impact factor: 8.739

4.  Mortality Associated With Heart Failure After Myocardial Infarction: A Contemporary Community Perspective.

Authors:  Yariv Gerber; Susan A Weston; Maurice Enriquez-Sarano; Cecilia Berardi; Alanna M Chamberlain; Sheila M Manemann; Ruoxiang Jiang; Shannon M Dunlay; Véronique L Roger
Journal:  Circ Heart Fail       Date:  2015-12-23       Impact factor: 8.790

Review 5.  Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

Authors:  Abesh Bera; Dwaipayan Sen
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 6.  A New Era of Cardiac Cell Therapy: Opportunities and Challenges.

Authors:  Ke Huang; Shiqi Hu; Ke Cheng
Journal:  Adv Healthc Mater       Date:  2018-12-13       Impact factor: 9.933

7.  Epicardial YAP/TAZ orchestrate an immunosuppressive response following myocardial infarction.

Authors:  Vimal Ramjee; Deqiang Li; Lauren J Manderfield; Feiyan Liu; Kurt A Engleka; Haig Aghajanian; Christopher B Rodell; Wen Lu; Vivienne Ho; Tao Wang; Li Li; Anamika Singh; Dasan M Cibi; Jason A Burdick; Manvendra K Singh; Rajan Jain; Jonathan A Epstein
Journal:  J Clin Invest       Date:  2017-02-06       Impact factor: 14.808

8.  Role of cathepsin D activation in major adverse cardiovascular events and new-onset heart failure after STEMI.

Authors:  Aylin Hatice Yamac; Emrah Sevgili; Sitki Kucukbuzcu; Muharrem Nasifov; Ziya Ismailoglu; Elif Kilic; Cilem Ercan; Parviz Jafarov; Hüseyin Uyarel; Ahmet Bacaksiz
Journal:  Herz       Date:  2015-04-25       Impact factor: 1.443

9.  Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study.

Authors:  João Pedro Ferreira; Kévin Duarte; Gilles Montalescot; Bertram Pitt; Esteban Lopez de Sa; Christian W Hamm; Marcus Flather; Freek Verheugt; Harry Shi; Eva Turgonyi; Miguel Orri; Patrick Rossignol; John Vincent; Faiez Zannad
Journal:  Clin Res Cardiol       Date:  2017-08-29       Impact factor: 5.460

10.  National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998-2010.

Authors:  Jersey Chen; Angela Fu-Chi Hsieh; Kumar Dharmarajan; Frederick A Masoudi; Harlan M Krumholz
Journal:  Circulation       Date:  2013-11-04       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.